Israel: Site Team Begins Collecting Inquiries for Study Participation

On November 25, 2012, the site team for our new Israeli study of MDMA-assisted psychotherapy for PTSD began collecting inquiries for participation in the study, beginning the screening process. In-person screening will begin on December 12, when our insurance policy goes into effect (which cost us about $8,000). This study will investigate the safety and effectiveness of MDMA-assisted psychotherapy in 10 people with chronic, treatment-resistant PTSD. While the sample size is small, the study will help us to develop our therapeutic approach, evaluate the effectiveness of the double blind, to compare the effectiveness of full (125 mg) versus active placebo (25 mg) doses of MDMA combined with psychotherapy, and to plan the design for future Phase 3 studies.